Deep Tech Startups

NeuroChat is a brain-computer interface platform that lets people with severe motor and speech impairments (cerebral palsy, ALS, stroke, multiple sclerosis, neurotrauma) type text and communicate through mental effort, with built-in online translation between languages. It also serves as a neurotraining system for developing cognitive functions such as attention, memory, and reaction speed by analyzing EEG data via a hardware headset and software interface.</parameter> <parameter name="founders">[{"full_name": "Наталия Галкина", "title": "Генеральный директор (CEO)"}, {"full_name": "Александр Лужин", "title": "Руководитель НИОКР НейроЧат"}, {"full_name": "Алеся Чичинкина", "title": "Директор по коммуникациям и международному развитию"}, {"full_name": "Юрий Мустафин", "title": "Технический директор (CTO)"}, {"full_name": "Александр Каплан", "title": "Научный руководитель проекта"}, {"full_name": "Игорь Зимин", "title": "Директор по развитию бизнеса"}, {"full_name": "Галина Ершова", "title": "Руководитель патронажной службы"}]

1 investor

NeuroEM Therapeutics develops MemorEM, a wearable head device that administers transcranial electromagnetic treatment to treat cognitive decline and Alzheimer's disease. The device targets patients with neurodegenerative diseases through a non-invasive, in-home treatment delivered by healthcare professionals.

1 investor

NeuroGenesis develops cell therapies for neurodegenerative diseases, leveraging its NG CELL platform to enhance stem cells for treating conditions like multiple sclerosis and ALS. The company is advancing Phase IIb clinical trials in Europe and Israel with a focus on remyelinating and regenerative cellular medicine.

1 investor

Neurolieve is a life-science company developing therapeutics for neuropathic and chronic pain, with expertise in neuroscience, clinical pain medicine and drug development. Its lead program, NLV-01, is built on protein-engineering technology contributed by co-founding partner LifeArc.

1 investor

Neurophyxia is developing a neuroprotectant compound (2-iminobiotin) for treating brain injury and tissue damage caused by stroke, cardiac arrest, and birth asphyxia. The compound is in Phase IIb/III clinical development.

1 investor

NeurOptics develops pupillometry technologies for clinical decision-making in critical care, neurology, neurosurgery, and emergency medicine. The company serves medical professionals and clinical researchers globally.

1 investor

NeuroSky provides biofeedback and biometric assessment solutions that help companies optimize hiring decisions, identify employee training needs, and improve workforce productivity through data-driven insights on cognitive performance and employee capabilities.

1 investor

NeuroTx develops AI-powered electroceutical and neurotechnology solutions that use neural decoding and non-invasive vagus nerve stimulation to support sleep quality, cognitive function, and metabolic health. The company integrates wearable devices, mobile applications, and machine learning to deliver personalized bio-signal-based interventions for consumers and patients.

1 investor

Neuroute is an AI-powered platform that accelerates clinical trial execution through patient recruitment, trial monitoring, and predictive analytics. It serves pharmaceutical companies and clinical research organizations conducting clinical trials.

1 investor

NeuroVigil develops portable, single-channel EEG brain-monitoring technology and analysis software for neurological research, disease diagnosis, and pharmaceutical clinical trials. Its systems are used to monitor sleep and brain activity for conditions such as ALS, Alzheimer's, and Parkinson's, serving researchers, drug developers, and patients.

1 investor

New Carbon Inc. (dba Darwin Carbon) is an advanced materials manufacturer producing carbon microfiber products—sheets, tapes, wires, and yarns—that combine structural, electrical, and thermal performance to replace metals, plastics, and concrete. It serves Tier I and Tier II suppliers in aerospace, defence, automotive, construction, energy, industrial, and consumer markets.

1 investor

New Dawn Bio produces wood grown through cell culture rather than harvested from trees. The company applies biotechnology to create cultured wood materials.

1 investor

New Frontier Bio is a biotechnology company with a cross-functional management team experienced in start-ups, science, strategy, and M&A across healthcare, biotechnology, and cosmetics.

1 investor

New Life Minds develops technology combining healthcare, life sciences, synthetic biology, and machine learning, with a stated focus on advancing brain evolution.

1 investor

New North Ventures is a venture capital firm run by former company operators and government professionals that invests in startups operating at the intersection of national security and economic resilience. It focuses on dual-use technology across national security, AI, and deep tech, helping founders navigate the space between startups and government.

1 investor

New Origin is a pure-play semiconductor foundry developing a silicon nitride (SiN) technology platform for integrated photonics, manufacturing photonic integrated circuits with low-loss propagation across visible to near-infrared wavelengths. It serves a global customer base in applications such as optical communication, HPC/AI, LiDAR, AR/VR, bio-sensing, imaging, and quantum, with operations rooted in Twente, The Netherlands.

1 investor

New Sapience builds "sapiens," a deterministic machine intelligence based on world-model directed-graph knowledge structures rather than machine learning or symbolic AI, used to automate decision-making and monitoring for critical infrastructure. It targets mission-critical operations across CISA-defined critical infrastructure sectors, offering expert human-in-the-loop judgement plus quantum-secure communications.

1 investor

An independent nonprofit academic research institution that convenes talent from academic, research, and medical institutions to advance collaborative genomic research and accelerate discoveries in the genetic basis of disease for clinical diagnosis and treatment.

1 investor

Newomics develops the UniESI system, a multiomics front-end platform using its M3 emitter and MEA chip "multispray" technologies for microflow and nanoflow LC-MS. The system serves as a dual nano/micro ion source for mass spectrometers, targeting applications in native MS, proteomics, metabolomics, and single-cell omics.

1 investor

Newronika is a spin-off of Italian research institutions Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico and the University of Milan that develops adaptive deep brain stimulation (αDBS) technology which responds to brain activity in real time. Its neuromodulation systems target Parkinson's disease and are being studied for a broader range of brain disorders, serving clinicians and patients.

1 investor

NewSpace Capital is a private equity firm focused on the space sector, investing in growth-stage deep-tech companies in the supply chain and downstream segments of the space market. It targets businesses with existing revenues that enable space technology and provide space-based applications for customers on Earth.

1 investor

NexGen Cloud provides AI cloud infrastructure built on NVIDIA hardware, offering GPU compute, single-tenant private cloud deployments, and on-demand platforms for AI model development and deployment. It serves enterprises, SMEs, startups, and individual practitioners across the AI lifecycle, with an emphasis on EU-sovereign and renewable-powered infrastructure.

1 investor

Nexgenia develops proprietary stimuli-responsive polymer-based reagents for molecular and cellular selection, diagnostics, and immunoassays. The company's technology enables faster and more efficient separation and analysis of cells and molecules through reversible phase transitions triggered by temperature, pH, or salt changes.

1 investor

Nexotx is a drug discovery company that identifies and develops medicines targeting previously undrugged biological pathways using chemical biology approaches. The company serves patients by translating novel scientific targets into therapeutic candidates.

1 investor